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Purpose
Although sentinel lymph node biopsy (SLNB) can accurately represent the axillary lymph
node (ALN) status, the false-negative rate (FNR) of SLNB is the main concern in the patients
who receive SLNB alone instead of ALN dissection (ALND).  
Materials and Methods
We analyzed 1,886 patients who underwent ALND after negative results of SLNB, retrospec-
tively. A logistic regression analysis was used to identify risk factors associated with a false-
negative (FN) result. Cox regression model was used to estimate the hazard ratio of factors
affecting disease-free survival (DFS). 
Results
Tumor located in the upper outer portion of the breast, lymphovascular invasion, suspicious
node in imaging assessment and less than three sentinel lymph nodes (SLNs) were signif-
icant independent risk factors for FN in SLNB conferring an adjusted odds ratio of 2.10
(95% confidence interval [CI], 1.30 to 3.39), 2.69 (95% CI, 1.47 to 4.91), 2.59 (95% CI,
1.62 to 4.14), and 2.39 (95% CI, 1.45 to 3.95), respectively. The prognostic factors affecting
DFS were tumor size larger than 2 cm (hazard ratio [HR], 1.86; 95% CI, 1.17 to 2.96) and
FN of SLNB (HR, 2.51; 95% CI, 1.42 to 4.42) in SLN-negative group (FN and true-negative),
but in ALN-positive group (FN and true-positive), FN of SLNB (HR, 0.64; 95% CI, 0.33 to
1.25) did not affect DFS.    
Conclusion
In patients with risk factors for a FN such as suspicious node in imaging assessment, upper
outer breast cancer, less than three harvested nodes, we need attention to find another
metastatic focus in non-SLNs during the operation. It may contribute to provide an exact
prognosis and optimizing adjuvant treatments.
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Introduction
Nevertheless, molecular profiles are acknowledged prom-
ising prognostic factor, axillary lymph node (ALN) status is
still the most important prognostic factor in breast cancer 
patients. This exact evaluation of ALN status is important.
Sentinel lymph node biopsy (SLNB) represents the status of
axillary involvement with more than 90% accuracy and 
develops a less complication than conventional axillary
lymph node dissection (ALND) [1,2]. Larger randomized
clinical trials have confirmed that the SLNB alone is a suffi-
cient method in terms of disease-free survival (DFS), overall
survival (OS), and moreover regional node recurrence event
compared to ALND in sentinel lymph node (SLN)negative
breast cancer patients [3,4]. The axillary recurrence after a
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tumor-negative SLNB on 14,959 patients showed that only
67 women developed an axillary recurrence, resulting in a
recurrence rate of 0.3% [5]. Several randomized controlled
trials also showed that axillary recurrence in SLN-negative
patients was very low [1,3,4]. According to these results,
SLN-negative patients do not undergo complete ALND any-
more, but we still have the issue of false-negative (FN) in
SLNB alone patients. False-negative rate (FNR) of the proce-
dure was between 4.6% and 16.7% [6] with an average of
8.4% overall [7]. In case of FN, the remnant disease may 
potentially influence on poor clinical outcomes. ALN metas-
tasis remain the most significant prognostic factor that dic-
tates the use of adjuvant chemotherapy (CTx) [8,9]; however,
in recent SLNB alone era a FN of SLNB can lead to under-
standing of disease and cannot provide exact information to
make decisions for adjuvant treatment. The issue of FN has
made the hesitation in the omission of further lymph node
dissection in SLN-negative patients. Therefore, we need to
pay particular attention to reducing FN in SLNB. The aim of
the present study is to identify the risk factors for a FN of
SLNB, and to analyze its clinical significance in patients with
breast cancer.
Materials and Methods
1. Patients
We retrospectively analyzed the data of patients who were
surgically treated for primary invasive breast cancer and
who underwent a SLNB followed by completion of an
ALND between January 1998 and December 2013 at Sever-
ance Hospital and Gangnam Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, Korea. Only patients
whose SLNB results were negative for malignancy docu-
mented in the permanent section were enrolled in the present
study. Women with carcinoma in situ or microinvasive car-
cinoma were excluded. We also excluded those who had 
received neoadjuvant CTx or preoperative hormonal ther-
apy. The study was approved by the Institutional Review
Board of Severance Hospital.
The clinical data from each patient was reviewed, and
pathological findings, including tumor size, tumor grade,
presence of multifocal or multicentric disease, and the num-
ber of lymph node metastases, were recorded. The results of
estrogen receptor and progesterone receptor analysis were
also recorded. The pathologic T stage and lymph node (N)
stage were classified according to the seventh edition of the
American Joint Committee on Cancer/Union for Interna-
tional Cancer Control classification system [10]. The modi-
fied Scarf-Bloom-Richardson grading system was used for
tumor grading. Most of the patients underwent breast and
axillary ultrasound (US), breast magnetic resonance imaging
(MRI) or positron emission tomography/computed tomog-
raphy (PET-CT) for preoperative evaluation. Preoperative
imaging studies were reviewed to evaluate axillary lymph
node status. The suspicious finding of ALN metastasis based
on the radiologist’s report, in any of these imaging studies
was considered as positive image finding. Adjuvant systemic
therapy and/or radiotherapy were considered according to
the standard guideline based on patient age, primary tumor
characteristics, and ALN status. Anti-hormone therapies
were used for patients according to their hormone receptor
status.
We categorized the results of SLNB as FN, true-negative
(TN), and true-positive (TP). A FN SLN was defined as neg-
ative SLNs but tumor-positive in non-SLNs. TN SLN was 
defined as negative SLN and TP SLN was defined as positive
SLN.
2. Procedure of SLNB 
The SLNB was performed using technetium-99m (99mTc)
tin colloid. Intradermal injection of 0.4 mL 30 MBq (0.8 mCi)
99mTc tin colloid diluted in normal saline solution was per-
formed in 3-4 subareolar and intradermal areas. SLN were
determined by employing a gamma detector in the operating
room (Gamma Detection System, Neoprobe Corporation,
Dublin, OH). The lymph node showing the highest radioac-
tivity was dissected, after which the gamma detector was
used again to confirm the correct lymph node. All radioac-
tive lymph nodes with a count equal to or greater than 10%
of the highest radioactive lymph node were removed. When
suspicious lymph nodes were found after a SLNB that were
not detected by the gamma probe, they were removed and
examined as non-SLNs. All patients underwent ALND after
a SLNB.
3. Statistical methods
A chi-square test was used to compare characteristics of
the FN and TN groups. A logistic regression analysis was
used to identify the risk factors for a FN in a SLNB. The 
Kaplan-Meier method and Cox regression model were used
for the survival analysis. To control for differences in the
baseline characteristics in each TP and FN group, a propen-
sity score matching was used with match tolerance 0.001 and
1:1 ratio. The model included survival related characteristics,
such as age at diagnosis, T stage, N stage, lymphovascular
invasion, nuclear grade, human epidermal growth factor 
receptor 2 (HER2) status, anti-hormonal therapy, and type of
breast surgery. We have incorporated changes in surgical
Seung Ah Lee, False-Negative in Sentinel Node Biopsy
VOLUME 50 NUMBER 3 JULY 2018  627
Table 1. Clinicopathological characteristics between false-negative and true-negative group for sentinel lymph node biopsy
Characteristic False-negative (n=179) True-negative (n=1,707) p-value
Age (yr)
 50 97 (54.2) 996 (58.3) 0.288
> 50 82 (45.8) 712 (41.7)
Mean (range) 50.0 (27-74) 50.0 (22-87)
Type of breast surgery
Total mastectomy 109 (60.6) 922 (54.0) 0.065
Breast conserving surgery 70 (39.4) 785 (46.0)
T stage
T1 101 (56.4) 1,173 (68.7) 0.007
T2 76 (42.5) 518 (30.3)
 T3 2 (1.1) 16 (0.9)
Tumor size, mean (range, cm) 2.10 (0.4-6.3) 1.80 (0.1-8.5)
Histology type
Infiltrating ductal 162 (90.5) 1,427 (83.5) 0.053
Lobular 4 (2.2) 71 (4.2)
Other 13 (7.3) 210 (12.3)
Modifier Bloom-Richardson score
I 41 (24.6) 362 (23.5) 0.679
II 84 (50.3) 739 (48.0)
III 42 (25.1) 438 (28.5)
Missing 12 ( 169 (
Estrogen receptor
Positive 119 (67.2) 1,132 (66.6) 0.863
Negative 58 (32.8) 568 (33.4)
Missing 2 ( 7 (
Progesterone receptor
Positive 111 (63.1) 988 (58.6) 0.260
Negative 65 (36.9) 699 (41.4)
Missing 3 ( 21 (
HER2
Positivea) 41 (27) 258 (17.8) 0.006
Negative 111 (73) 1,195 (82.2)
Missing 27 ( 255 (
Subgroup
HR(+)HER2(–) 84 (53.8) 862 (57) 0.018
HR(+)HER2(+) 25 (16) 138 (9.1)
HR(–)HER2(+) 16 (10.3) 120 (7.9)
HR(–)HER2(–) 31 (19.9) 392 (25.9)
Lymphovascular invasion
Positive 20 (18.5) 73 (8.3) 0.001
Negative 88 (81.5) 806 (91.7)
Missing 71 ( 829 (
No. of dissected sentinel nodes
1 78 (43.6) 520 (30.4) 0.002
2 48 (26.8) 446 (26.1)
3 24 (13.4) 280 (16.4)
4 12 (6.7) 216 (12.6)
 5 17 (9.5) 246 (14.4)
(Continued to the next page)
technique by incorporating. All statistical analyses were per-
formed using the SPSS ver. 24.0 (IBM Corp., Armonk, NY).
A p-value less than 0.05 was considered to indicate a statis-
tically significant difference.
Results
To assess risk factors for false-negativity in SLNB, 1,886 
patients who underwent back up ALND after negative 
results of SLNB were enrolled in the present study. Among
them, 1,707 patients have TN results, 179 patients were 
revealed to have a FN in the SLNB, and 24 patients had more
than four positive axillary lymph nodes. The clinicopatho-
logic characteristics of patients are presented in Table 1.
Compared to those with a TN, factors found to be signifi-
cantly associated with a FN in the SLNB included a primary
tumor size > 2 cm, HER2-positive, lymphovascular invasion
(LVI), positive results of preoperative axilla image studies
and tumor location in the upper outer breast. There were 
patients with a single harvested SLN during the procedure.
These represented 78 patients (43.6%) in the FN group and
520 patients (30.4%) in the TN group, respectively. There
were 77 patients (45.8%) with suspicious imaging study 
result in the FN group and 372 patients (22.8%) in the TN
group. Adjuvant CTx and radiation therapy were provided
more frequently in those with a FN in the SLNB (p < 0.001
and p=0.033, respectively) (Table 1).
In the univariate analysis of risk factors for false-negativity
in SLNB, odds ratio of tumor size > 2 cm, tumor in the upper
outer quadrant of the breast, ductal histologic type, the pres-
ence of LVI, and positive results in imaging assessment were
1.70, 1.78, 1.88, 2.51, and 2.861, respectively. Three or more
dissected SLNs had a statistically significant lower odds ratio
for a FN in the SLNB than 1 or 2 dissected SLNs (odds ratio
of 0.57 and 0.37, respectively). A multivariate logistic regres-
sion model identified that tumor located in the upper outer
quadrant of the breast, the presence of LVI, positive result in
imaging assessment, and the number of dissected SLNs ( 2)
still remained significant independent risk factors for a FN
in the SLNB (adjusted odds ratio of 2.10 [95% confidence 
interval, 1.30 to 3.39], 2.69 [95% confidence interval, 1.47 to
4.91], 2.59 [95% confidence interval, 1.62 to 4.14], and 2.39
[95% confidence interval, 1.45 to 3.95], respectively) (Table 2).
During the median 62.0 months (range, 1 to 174 months)
of follow-up period, 18 patients (10.1%) had a recurrence and
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Table 1. Continued
Characteristic False-negative (n=179) True-negative (n=1,707) p-value
No. of metastatic lymph nodes
1 123 (68.7) - -
2 26 (14.5) -
3 6 (3.4) -
 4 24 (13.4) -
Tumor location
Upper outer 113 (63.1) 829 (49.0) < 0.001
Upper inner 21 (11.7) 367 (21.7)
Lower outer 23 (12.8) 151 (8.9)
Lower inner 6 (3.4) 88 (5.2)
Central 16 (8.9) 257 (15.2)
Imaging assessment
Positiveb) 77 (45.8) 372 (22.8) < 0.001
Negativec) 91 (54.2) 1,258 (77.2)
Adjuvant treatment
Chemotherapy 169 (96.6) 1,043 (62.1) < 0.001
Anti-hormone therapy 121 (69.5) 1,171 (69.2) 0.928
Radiation therapy 97 (55.1) 794 (46.5) 0.033
Values are presented as number (%). HR, hormone receptor; HER2, human epidermal growth factor receptor 2. a)HER-2 pos-
itive was defined by three positive on immunohistochemistry or amplification on fluorescence in situ hybridization, b)Image
positive was defined as suspicious axillary lymph nodes on one or more imaging studies, c)Image negative was defined as
non-suspicious axillary lymph nodes on all imaging studies.
628 CANCER  RESEARCH  AND  TREATMENT
nine patients (5.0%) died in the FN group (n=174). Two 
patients (1.1%) had a loco-regional recurrence, and 16 (8.9%)
had a systemic relapse. In the TN group (n=1,707), 72 (4.2%) 
patients had a recurrence, and 53 (3.1%) women died.
Twenty-two of 72 (1.3%) had a loco-regional recurrence, and
50 (2.9%) had a systemic relapse. We also analyzed the sur-
vival of TP patients to see whether there exists a difference
between FN and TP among ALN-positive patients according
to SLN positivity. In TP group, 10.2% patients had experi-
enced recurrence and 5.3% of them died. Among them, 2.3%
had loco-regional recurrence and 7.9% had systemic recur-
rence.
In multivariate analysis, the prognostic factors for DFS in
SLN-negative group (TN and FN) were tumor size > 2 cm
(hazard ratio [HR], 1.86; p=0.009) and false-negativity (HR,
2.51; p=0.002). On the other hand, in the ALN-positive group
(TP and FN), false-negativity (HR, 0.64; p=0.191) did not 
affect the prognosis of the DFS and only tumor size and
nodal status were statistically significant prognostic factors
(Table 3). The 5-year DFS rate and OS rate in the FN group
were 89.2% and 94.6%, respectively, compared to 95.5% and
97.3% in the TN group (Fig. 1). To compensate for differences
of factors affecting survival between FN and TP group, 
patients were selected in each group and baseline character-
istics of each patient were well balanced (S1 Table). The 
adjusted 5-year DFS rate was same in both groups (89.3%).
OS rate was 96.1% in the FN group and 96.7% in the TP
group. There was no statistical difference between FN and
TP in terms of survival outcomes (S2A and S2B Fig.).
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Table 2. Multivariate analysis for risk factor of false-negative in sentinel lymph node biopsy
Variable Odds ratio 95% CI p-value
Tumor size > 2 cm 1.17 0.73-1.87 0.510
Tumor location, UO 2.10 1.30-3.39 0.002
Histology, ductal 1.61 0.77-3.36 0.185
HER2, positive 1.64 0.98-2.74 0.058
LVI, positive 2.69 1.47-4.91 0.001
Imaging assessment, positive 2.59 1.62-4.14 < 0.001
No. of dissected SLN,  2 2.39 1.45-3.95 0.001
CI, confidence interval; UO, upper outer; HER2, human epidermal growth factor receptor 2; LVI, lymphovascular invasion;
SLN, sentinel lymph node.
Variable
SLN-negative (TN and FN) ALN-positive (FN and TP)
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age > 50 yr 1.02 0.35-1.12 0.116 1.21 0.66-2.20 0.526
Tumor size > 2 cm 1.86 1.17-2.96 0.009 2.20 1.17-4.11 0.014
N stage, N  2 - - - 2.13 1.12-4.06 0.022
Histologic grade 1.02 0.58-1.78 0.941 1.56 0.88-3.05 0.118
LVI 0.99 0.35-2.80 0.989 0.71 0.35-1.42 0.330
HR positivity 0.50 0.62-3.89 0.337 0.91 0.36-2.29 0.835
HER2, positive 0.51 0.24-1.08 0.079 0.59 0.29-1.22 0.157
False-negative 2.51 1.42-4.42 0.002 0.64 0.33-1.25 0.191
Breast surgery, TM 0.67 0.39-1.15 0.148 0.97 0.48-1.97 0.925
Chemotherapy 0.75 0.41-1.26 0.339 0.75 0.62-1.64 0.862
Anti-hormone therapy 0.83 0.29-2.36 0.725 0.61 0.27-1.40 0.250
Table 3. Multivariate analysis of prognostic factor for disease-free survival in patients undergoing sentinel lymph node
biopsy  
SLN, sentinel lymph node; TN, true-negative; FN, false-negative; ALN, axillary lymph node; TP, true-positive; CI, confidence
interval; LVI, lymphovascular invasion; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TM, total
mastectomy. 
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Discussion
ALN status is still one of the most important prognostic
factors, and provide important information to decide an 
appropriate adjuvant treatment in breast cancer patients.
SLNB has become the standard treatment of choice for eval-
uation of ALN status after releasing the results of NSABP 
B-32 trial [4]. The majority of surgeons does not complete
ALND in patients with SLN-negative. In the NSABP B-32
trial, there was 9.8% FNR in SLNB followed by ALND group
[11], considering that, there might be about 10% FN patients
in SLNB alone group. Although, there was no significant dif-
ference in survival outcomes between two groups [4], about
10% of hidden FN patients could not obtain accurate infor-
mation of ALN status compared with TN patients and were
spared from appropriate adjuvant treatments. In recent
SLNB alone era, information about ALN status is acquired
through SLNB only. Therefore, efforts should be made to 
decrease the FN in SLNB. 
There are several studies that have identified clinical fac-
tors predictive of a FN in a SLNB [12-17]. They mentioned
tumor size, multifocal-multicentric disease, location of
tumor, and number of removed SLN as risk factors. All of
these studies were focused on FNR, in which the FN results
were compared with TP results. In clinical practice, however,
distinguishing whether a negative result in a SLNB is truly
negative or actually positive is more important. In the pres-
ent study, we have assessed the risk factors of FN in SLNB
and analyzed effect of false-negative results to patients’ sur-
vival. Tumor location, LVI, positive result in imaging 
assessment, and the number of dissected SLNs were the 
independent factors associated with a FN in the SLNB. 
Among these risk factors, we newly found that patients
with suspicious nodes in any kinds of preoperative imaging
studies had a greater risk of FN with odd ratio 2.59 in a
SLNB. The sensitivity and specificity to detect ALN metas-
tasis with preoperative axillary US in the literature ranges
from 25% to 87% and 77% to 100%, respectively [18-20].
Combining axillary US with breast MRI or PET-CT may 
enhance in predicting ALN metastasis because multimodal
imaging studies improve the diagnostic performance com-
pared with axillary US alone [21-23]. Nevertheless, preoper-
ative suspicious finding in imaging studies is not enough to
determine ALND without SLNB. Patients with suspicious
ALN in imaging modality who showed negative result from
preoperative fine needle aspiration or core needle biopsy
could be indicated for SLNB if they do not have matted ALN.
A possible reason for increased FNR in suspicious ALNs in
imaging studies is that SLNs and radiologically suspicious
nodes may not be identical. Wang et al. [24] reported that
38.3% of suspicious ALNs in US were indeed SLNs and FNR
was decreased from 11.3% to 2.8% when SLNB with addi-
tional US-guided suspicious node excision was done. Gen-
erally, the metastatic tumor burden in suspicious lymph
nodes in imaging studies is larger than that of benign looking
nodes. The increased tumor burden may obstruct the peri-
nodal lymphatic channel; then lymphatic drainage might 
Cancer Res Treat. 2018;50(3):625-633
Fig. 1.  Disease-free survival and overall survival according to the results of sentinel lymph node (LN) biopsy. (A) Disease-
free survival analysis between true-negative and false-negative group (p=0.001). (B) Overall survival analysis between true-
negative and false-negative group (p=0.312). 
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bypass the true metastatic ALN which can lead to FN of
SLNB. In the present study, only 17.1% of patients with sus-
picious node in imaging studies had metastasis, which sug-
gest that preoperative radiological suspicious ALNs are not
contraindication for SLNB. However, clinicians should be
more careful in evaluating SLN and consider a potential of
FN during a SLNB in such cases.
Although there are few studies that report LVI as a risk
factor for a FN in a SLNB, we found that patients with LVI
had FN more frequently. Lymphatic channels that became
progressively infiltrated by tumor cells may not allow the
passage of radioactive dye [25]. This might explain the posi-
tive correlation of LVI with FN in SLNB. Several studies have
already shown that LVI is associated with increased risk of
axillary involvement [26,27]. Consequently, a tumor with
LVI may have a greater chance of a FN in a SLNB by lym-
phatic obliterans. 
Other risk factors such as tumor location [12,13] and the
number of dissected SLNs [12,15,17] were also shown to be
significant risk factors for a FN in other studies. Our findings
are concordant with previous studies that FN results are
more likely to be observed when a tumor is located in the
upper outer quadrant of the breast and when only a single
SLN is harvested. The correlation between the number of 
removed SLN and FNR has been reported in previous stud-
ies. However, the best cut-off value of number of harvested
SLN of reducing the FNR is inconsistent. Some studies sug-
gested up to four removed SLNs increased diagnostic accu-
racy [28]. Our result shows less than three harvested SLNs
increase the FN with 2.3 of odds ratios. 
The Early Breast Cancer Trialists’ Collaborative Group
showed that CTx is important for decreasing recurrence and
increasing survival in early breast cancer patients [29]. In
clinical practice, ALN metastases have been recognized as an
essential indication for adjuvant CTx. In terms of optimizing
adjuvant treatments, the risk of FN can be more importantly
considered in individual patients. FN in SLNB may deprive
the patients who actually have positive axillary lymph nodes
of the opportunity for CTx, and adversely influence survival
outcomes. In the present study, we have analyzed the clinical
significance of FN group compared to TN group. False-neg-
ative result of SLNB is most powerful independent prognos-
tic factor (HR, 2.51; 95% confidence interval, 1.42 to 4.42)
affecting DFS in this group, but this effect was not showed
in FN and TP group. Patients in the FN group presented a
similar loco-regional recurrence rate compared to patients in
the TN group (1.1% vs. 1.5%), but the FN group had a greater
systemic recurrence rate than the TN group (8.9% vs. 2.9%,
p < 0.001, data not shown). Patients with FN in the SLNB had
a worse DFS than those with TN in the SLNB, despite 96.6%
of patients with a FN in the SLNB receiving adjuvant CTx.
Moreover, some patients had extended axillary disease, and
13.4% of women were revealed to have four or more positive
ALNs. The National Comprehensive Cancer Network clini-
cal practice guidelines advocate that irradiation to the infra-
clavicular region and supraclavicular area should be recom-
mended for patients with four or more positive ALNs [9].
With an understanding that these patients might result in 
undertreatment, we can expect that they would probably dis-
play a poorer prognosis. Thus, we suggest that making an
effort to discover metastatic non-SLNs is necessary in 
patients with a high risk for a FN in a SLNB. It may reduce
the chance of masking the FN cases and allow more appro-
priate adjuvant treatment including CTx and regional radio-
therapy for these patients. Refined adjuvant treatments by
identifying FNs may contribute to ameliorate oncologic out-
come. Preoperative multi-imaging studies can provide infor-
mation on risk factors for a FN, although further study is
needed to evaluate the appropriate combination of imaging
modalities. We also compared the survival of FN and TP 
patients to see whether there exists a difference according to
SLN positivity which resulted in no difference between two
groups as expected since these patients all received ALND.
The present study has several limitations. Our data were
based on a retrospective cohort from two different institutes.
Protocol of pathologic evaluation for SLNs was not identi-
cally established in an aspect of serial section or additional
immunohistochemical stain which can influence FN of
SLNB. However, the pathologic evaluation protocol has been
standardized in the later period of this study and we ana-
lyzed a relatively large number of patients compared to pre-
vious studies. Another limitation is that we did not confirm
all of radiologically suspicious ALNs with core needle biopsy
or fine needle aspiration cytology.
In summary, SLNB has been accepted standard axillary
staging surgery for patients with clinically node-negative
breast cancer. We found risk factors for a FN of a SLNB and
showed a worse outcome of patients with FN compared with
those with TN. In patients with LVI, tumor located at the
upper outer quadrant of the breast, positive ALN in preop-
erative imaging assessment, and with less than three har-
vested SLNs, additional effort to find suspicious non-SLNs
during SLNB may contribute to optimizing adjuvant treat-
ments.
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